Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Public ClinicalTrials.gov record NCT02827838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Study identification
- NCT ID
- NCT02827838
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Enrollment
- 17 participants
Conditions and interventions
Conditions
- Human Papillomavirus Infection
- Stage I Oral Cavity Squamous Cell Carcinoma
- Stage I Oropharyngeal Squamous Cell Carcinoma
- Stage II Oral Cavity Squamous Cell Carcinoma
- Stage II Oropharyngeal Squamous Cell Carcinoma
- Stage III Oral Cavity Squamous Cell Carcinoma
- Stage III Oropharyngeal Squamous Cell Carcinoma
- Stage IVA Oral Cavity Squamous Cell Carcinoma
- Stage IVA Oropharyngeal Squamous Cell Carcinoma
- Stage IVB Oral Cavity Squamous Cell Carcinoma
- Stage IVB Oropharyngeal Squamous Cell Carcinoma
- Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
- Durvalumab Biological
- Laboratory Biomarker Analysis Other
- Therapeutic Conventional Surgery Procedure
Biological · Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2016
- Primary completion
- Apr 21, 2022
- Completion
- Apr 21, 2022
- Last update posted
- Mar 16, 2025
2017 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Cancer Center of Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02827838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02827838 live on ClinicalTrials.gov.